48,828 RSUs awarded to Organogenesis (ORGO) board director

Rhea-AI Filing Summary

Organogenesis Holdings Inc. director Gilberto Quintero reported an equity award of 48,828 restricted stock units (RSUs) of Class A common stock under the company’s 2018 Equity Incentive Plan. Each RSU converts into one share upon vesting, and the award vests in full on February 15, 2027. Following this grant, Quintero directly holds 239,073 shares of Class A common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Quintero Gilberto

(Last) (First) (Middle)

C/O ORGANOGENESIS HOLDINGS INC.

85 DAN ROAD

(Street)

CANTON MA 02021

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Organogenesis Holdings Inc. [ ORGO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/18/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	02/18/2026		A(1)		48,828	A	$0	239,073	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in full on February 15, 2027.

	/s/ William R. Kolb, Attorney-in-Fact	02/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Organogenesis (ORGO) report for Gilberto Quintero?

Organogenesis reported that director Gilberto Quintero received a grant of 48,828 restricted stock units of Class A common stock. These RSUs were awarded under the 2018 Equity Incentive Plan as a form of equity compensation rather than an open-market purchase.

When do Gilberto Quintero’s Organogenesis (ORGO) RSUs vest?

The 48,828 restricted stock units granted to Gilberto Quintero vest in full on February 15, 2027. Once vested, each RSU entitles him to receive one share of Organogenesis Class A common stock, subject to the plan’s terms and conditions.

How many Organogenesis (ORGO) shares does Gilberto Quintero hold after this Form 4?

After the reported RSU grant, Gilberto Quintero directly holds 239,073 shares of Organogenesis Class A common stock. This figure reflects his direct ownership position as reported in the Form 4 following the equity award transaction.

What type of security was granted to Gilberto Quintero by Organogenesis (ORGO)?

Gilberto Quintero received restricted stock units, or RSUs, tied to Organogenesis Class A common stock. Each RSU represents the contingent right to receive one share upon vesting, in accordance with the company’s 2018 Equity Incentive Plan.

Was cash paid for Gilberto Quintero’s Organogenesis (ORGO) RSU grant?

No cash payment is indicated for this RSU grant, which is reported with a per-share transaction price of 0.0000. The award represents stock-based compensation under the company’s equity incentive plan rather than a market purchase of shares.

Under which plan were Gilberto Quintero’s Organogenesis (ORGO) RSUs granted?

The restricted stock units granted to Gilberto Quintero were issued under the Organogenesis Holdings Inc. 2018 Equity Incentive Plan. This plan provides equity-based compensation to eligible participants, aligning their interests with long-term shareholder value.